Insomnia drug company, TransOral, raises $40M more
TransOral Pharmaceuticals, a Pt. Richmond, Calif. developer of a drug that treats insomnia, has raised $40 million in a fourth round of funding.
See the company’s announcement here.
The investor syndicate was led by New Enterprise Associates (NEA) and included follow-on investments by New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures, Peninsula Equity Partners, and Hercules Technology Growth Capital.
Next Story: Xradia raises $7M for 3D x-ray microscopes and imaging
Previous Story: Update: BA Ventures relaunches as Scale Venture Partners, clarifies investors
Tags: co:TransOral, deal, inv:Hamilton-BioVentures, inv:Hercules-Technology-Growth-Capital, inv:Interwest-Partners, inv:Montreux-Equity-Partners, inv:New-Enterprise-Associates, inv:New-Leaf-Venture-Partners, inv:Peninsula-Equity-Partners, inv:Vivo-Ventures
VentureBeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, GamesBeat
- Anthony Ha, Assistant Editor, VentureBeat
- Camille Ricketts, Lead Writer, GreenBeat
- Paul Boutin, Writer, VentureBeat
- Kim-Mai Cutler, Writer, VentureBeat
- Matthaus Krzykowski, Mobile Consultant & Coordinator
VentureBeat Start-Up Index
An index of the hottest startups, measured by trends in their traffic, news coverage, buzz and funding.